The Filing Desk

Corcept Therapeutics vs Emergent BioSolutions

Corcept Therapeutics CORT · Emergent BioSolutions EBS · Pharmaceuticals

Corcept Therapeutics reported revenue of $761 million in fiscal 2025, about the same as Emergent BioSolutions' $743 million in fiscal 2025. Corcept Therapeutics' revenue grew 12.8% in its latest year, and Emergent BioSolutions' fell 28.8%. Corcept Therapeutics had an operating margin of 5.9%, against 13.5% at Emergent BioSolutions. Free cash flow was $142 million at Corcept Therapeutics and $157 million at Emergent BioSolutions.

Side by side

Corcept TherapeuticsEmergent BioSolutions
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$761M$743M
Revenue growth12.8%−28.8%
Revenue growth a year, last 5 years16.6%−14.0%
Gross margin98.3%56.1%
Operating margin5.9%13.5%
Net margin13.1%7.1%
Free cash flow$142M$157M
Free cash flow margin18.6%21.1%
Return on capital15.7%6.4%
Net debt to EBITDA−8.1x2.0x
Dividends and buybacks$173M$25M
Change in diluted share count5.7%7.0%
Last close$64.98$5.15
P/E at the last close51.2×—
Insider trades, last 12 monthsbought $3.3 million, sold $93.4 millionsold $840,301
Piotroski F-score3 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Corcept TherapeuticsEmergent BioSolutions
Operating margin
Percent of revenue
Corcept TherapeuticsEmergent BioSolutions
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Corcept TherapeuticsEmergent BioSolutions

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Corcept Therapeutics and Emergent BioSolutions pages.